Back to News
Market Impact: 0.35
AbbVie Gains FDA Approval For Subcutaneous Induction Of SKYRIZI In Crohn's Disease
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
The FDA approved a subcutaneous induction regimen of AbbVie’s SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease. The regimen gives patients a new option to begin treatment at home.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ABBV0.80
More News
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Trump set to announce plan by Audi to build a U.S. factory in Georgia, source says
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Instacart reportedly discussed selling itself with DoorDash and Uber
- Biotech stocks are surging. How investors can play the new drug innovation boom